The abstract is read at the publisher; the summary is JClub's.
Danvatirsen plus pembrolizumab did not improve overall response rate versus pembrolizumab alone in first-line recurrent/metastatic head and neck squamous cell carcinoma with PD-L1 CPS ≥1.
- Why it matters: STAT3 is linked to a pro-oncogenic tumor microenvironment, and this trial tested whether adding a STAT3-targeting antisense oligonucleotide could enhance immunotherapy benefit.
- What they did: In a multicenter randomized open-label phase II study (NCT05814666), 66 treated patients with previously untreated R/M head and neck squamous cell carcinoma and PD-L1 CPS ≥1 received danvatirsen 3 mg/kg weekly plus pembrolizumab 200 mg every 3 weeks or pembrolizumab alone, with ORR by RECIST v1.1.
- The result: Final ORRs were 15.6% with danvatirsen plus pembrolizumab and 14.3% with pembrolizumab alone (risk difference 1.3; P = 1), while treatment-emergent adverse events were higher in the combination arm (97.8% vs. 85.7%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.